Prognostic Factors and Survival Rate of Ampulla of Vater Cancer after Curative Surgery by 지훈상 et al.
근치적 절제술 후 Vater씨 팽대부암의 예후 인자 및 생존율 분석
Departments of Surgery and 3Pathology, Yonsei University 
College of Medicine, Seoul, Korea, 1M.D. Anderson Cancer 
Center, 2Department of Surgery, Capital Armed Forces 
General Hospital
Prognostic Factors and Survival Rate of Am-
pulla of Vater Cancer after Curative Surgery
Young Ki Hong, M.D., Joon Jeong, M.D.1, Joon Seong 
Park, M.D.2, Eun Joo Jung, M.D., Yong Sang Lee, M.D., 
Young Nyun Park, M.D.3, Dong Sup Yoon, M.D., Jin Sup 
Choi, M.D., Woo Jung Lee, M.D., Hoon Sang Chi, M.D. 
and Byong Ro Kim, M.D.
Purpose: Ampulla of Vater cancer has a more favorable 
prognosis than other malignant tumors of the periampullary 
region, but prognostic factors have not been identified. The 
aim of this study was to evaluate the prognostic factors of 
ampulla of Vater cancer from a single hospital experience.
Methods: The medical records of the 102 patients with 
ampulla of Vater cancer which underwent curative surgery 
between 1992 and 2002, were reviewed. All specimens were 
critically reviewed by an expert pathologist. The relationships 
between survival and the clinicopathological variables were 
assessed.
Results: In 120 patients that presented with ampulla of 
Vater cancer, 102 (85%) were resected. The 5 year survival 
rate was 69.1%. A univariate analysis showed the survival 
was closely related to gender, the tumor gross morphology, 
invasion depth and lymph node metastasis. A multivariate 
analysis identified two significant factors; the depth of 
invasion and gender. Twenty nine of the 102 patients 
suffered a recurrence.
Conclusion: The depth of invasion and gender were 
independent significant prognostic factors of resectable 
ampulla of Vater cancer. Careful observation is essential for 
liver metastasis after surgery, especially in patients that have 
these factors. (J Korean Surg Soc 2004;66:212-215)
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